BioNTech Nearly Doubled Median Survival — The Trial Curve Matters More Than the Headline
Gotistobart delivered a statistically significant overall-survival benefit in a Phase 3 lung-cancer study, but approval value depends on the hazard ratio, safety, durability and full trial design—not one median.
15 Sep 2026, 6:48 PM IST